365telugu.com online news, Hyderabad, August 25, 2025: Thermo Fisher Scientific has announced a series of major investments to boost India’s biopharma infrastructure, underlining its long-term commitment to the country. The announcement was made at the Biopharma Conclave 2025, where company leaders engaged with representatives from government, industry, and academia.
India’s biopharma sector, valued at $8.1 billion in 2024, is projected to nearly double to $15.9 billion by 2030. Growth is being driven by favorable global regulatory conditions, increasing market maturity, and the rising demand for advanced therapies.
“India’s biopharma sector is on the brink of rapid growth, and Thermo Fisher is committed to supporting this transformation,” said Tony Acciarito, President, Asia Pacific & Middle East, Africa. “Our integrated solutions across the value chain will help accelerate innovation, improve productivity, and ensure quality outcomes. India is one of our fastest-growing markets, and we are building capabilities here to match its vast potential.”
As part of this strategy, Thermo Fisher will establish two advanced facilities in Genome Valley, Hyderabad, both scheduled to open by the end of 2025.
- Bioprocess Design Center (BDC): Developed in collaboration with the Telangana Government, this facility will focus on bioprocessing expertise and process scale-up to accelerate the development of next-generation therapies.
- Customer Experience Center (CEC): A hub for showcasing advanced instrumentation and workflow solutions across molecular biology, proteomics, diagnostics, and cell and gene therapy. The CEC will also provide hands-on support for technology adoption, method development, and workforce skill-building.
“Challenges around access to advanced technologies and expertise have slowed the pace of India’s biopharma sector,” noted Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. “The BDC and CEC will directly address these gaps, helping start-ups and established players alike bring therapies to market faster and to international quality standards.”
Read This also…Croma Unveils Festive Tech Deals for Ganesh Chaturthi – Savings Up to 60%*
The conclave, organised by CPHI and Informa Markets (a division of Informa PLC), spotlighted key industry priorities such as advancing biologics, cell and gene therapies, workforce development, and women’s participation in STEM. A leadership panel also examined strategies for building sustainable and profitable biologics and biosimilars businesses in the coming five years.